178 related articles for article (PubMed ID: 17475966)
21. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
[TBL] [Abstract][Full Text] [Related]
22. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.
Lin C; Itti E; Haioun C; Petegnief Y; Luciani A; Dupuis J; Paone G; Talbot JN; Rahmouni A; Meignan M
J Nucl Med; 2007 Oct; 48(10):1626-32. PubMed ID: 17873129
[TBL] [Abstract][Full Text] [Related]
23. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor.
Scheer MG; Stollman TH; Vogel WV; Boerman OC; Oyen WJ; Ruers TJ
J Nucl Med; 2008 Jun; 49(6):887-91. PubMed ID: 18483084
[TBL] [Abstract][Full Text] [Related]
24. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
[TBL] [Abstract][Full Text] [Related]
25. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
26. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
27. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases.
Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV
Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.
Cheze-Le Rest C; Metges JP; Teyton P; Jestin-Le Tallec V; Lozac'h P; Volant A; Visvikis D
Nucl Med Commun; 2008 Jul; 29(7):628-35. PubMed ID: 18528185
[TBL] [Abstract][Full Text] [Related]
30. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
[TBL] [Abstract][Full Text] [Related]
31. PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Dimitrakopoulou-Strauss A; Strauss LG; Rudi J
Q J Nucl Med; 2003 Mar; 47(1):8-13. PubMed ID: 12714949
[TBL] [Abstract][Full Text] [Related]
32. Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer.
McLeish AR; Lee ST; Byrne AJ; Scott AM
ANZ J Surg; 2012; 82(1-2):30-5. PubMed ID: 22507492
[TBL] [Abstract][Full Text] [Related]
33. The role of FDG-PET in the selection of patients with colorectal liver metastases.
Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
[TBL] [Abstract][Full Text] [Related]
34. PET-CT accurately predicts the pre-operative characteristics of colorectal hepatic metastases.
Jones C; Badger SA; McKie LD; Diamond T; Taylor MA; Lynch TB
Eur J Surg Oncol; 2012 Dec; 38(12):1184-8. PubMed ID: 22883963
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer.
Izuishi K; Yamamoto Y; Mori H; Kameyama R; Fujihara S; Masaki T; Suzuki Y
Oncol Rep; 2014 Feb; 31(2):701-6. PubMed ID: 24297035
[TBL] [Abstract][Full Text] [Related]
36. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography.
Sze DY; Iagaru AH; Gambhir SS; De Haan HA; Reid TR
Hum Gene Ther; 2012 Jan; 23(1):91-7. PubMed ID: 21895536
[TBL] [Abstract][Full Text] [Related]
37. PET-CT as a predictor of outcome in resectable colorectal liver metastases.
Jones C; Badger SA; Stevenson M; Diamond T; McKie LD; Taylor MA; Wilson RH; Lynch TB
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):466-72. PubMed ID: 24445726
[TBL] [Abstract][Full Text] [Related]
38. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
39. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
[TBL] [Abstract][Full Text] [Related]
40. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors.
Kaira K; Okumura T; Ohde Y; Takahashi T; Murakami H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
J Nucl Med; 2011 May; 52(5):705-11. PubMed ID: 21498541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
